The Value of Real-time CGM in Reducing Hospitalizations Among Plan Beneficiaries of Advanced Age

• Release Date: January 14, 2021
• Expiration Date: September 2, 2022
• Estimated Time to Complete Activity: 0.5 hours
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

David G. Marrero, PhD Director, Center for Border Health Disparities Professor of Public Health and Medicine University of Arizona Health Sciences Click here for biography

Target Audience

• This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview 

The vast majority of members with diabetes have an A1C above American Diabetes Association (ADA) targets, putting them at risk for other costly comorbidities. Studies have shown that a lower A1C reduces microvascular and macrovascular complications associated with type 1 diabetes (T1D). To effectively address these clinical challenges and elicit improvements across 29 indices of glycemic control and glycemic variability, continuous glucose monitoring (CGM) has been endorsed by various professional endocrinology-centered organizations. To further optimize the clinical management of T1D and T2D, managed care and payer professionals should remain cognizant of the detrimental effects of administrative burden and restrictive benefit design on provider prescribing and member access to appropriate clinical interventions. Seamless, real-time access to CGM technology under the pharmacy benefit is essential to facilitate prescribing and use of this proven intervention among patients and providers, respectively. This educational activity is designed to improve knowledge and competence among managed care professionals of the management of diabetes through CGM.

Educational Objectives 
After completing this activity, the participant should be better able to: 

• Identify key outcome measures for diabetes management in aging populations, such as time-in-range, incidence of hypoglycemic events, and hemoglobin A1C
• Describe the value of real-time continuous glucose monitoring (rtCGM) in reducing morbidity and resource utilization among beneficiaries of advanced age and the subsequent impact of health technology intervention on total cost of care
• Characterize the role of rtCGM as part of a comprehensive diabetes management strategy in aging populations
• Recognize access barriers preventing appropriate rtCGM utilization in elderly patients with public insurance and distinguish benefit design approaches to address these barriers

ACCREDITATION

Physician Continuing Medical Education
Accreditation Statement 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates these enduring materials for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation
Medical Education Resources designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
UAN: 0816-9999-21-051-H01-P.  
This activity is certified as Knowledge-based CPE.

Nursing Continuing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Medical Education Resources is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Dexcom. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period January 14, 2021 through September 2, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.